This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
XELJANZ® (tofacitinib citrate) Prescribing Information and Maxtrex (methotrexate) Prescribing Information. Adverse event reporting can be found at the bottom of the page.
Tofacitinib should only be used if no suitable treatment alternatives are available in patients:
These risks are considered class effects and relevant across all approved indications of JAKi in inflammatory and dermatologic diseases.
Professor Raj Sengupta is a Consultant Rheumatologist and Clinical Lead for Ankylosing Spondylitis (AS) at The Royal National Hospital for Rheumatic Diseases, Bath (RNRHD).
He is a member of the BSR Spondyloarthritis Special Interest Group, the BSR axSpA Biologics Guidelines Committee and a member of ASAS (Assessment of Spondyloarthritis International Society). Professor Sengupta is a medical advisor for the National Axial Spondyloarthritis Society (NASS) and is Chair of the Trustees and current Treasurer of the British Society for Spondyloarthritis (BRITSpA).
He has been nominated as a NICE Clinical Expert at a number of appraisals for targeted therapies in axSpA. Professor Sengupta was the recipient of the 2016 NASS Patients Choice award for the Best care provided by a Rheumatologist.
He is the principal investigator in several national and international clinical trials in Axial Spondyloarthritis (axSpA). He has a number of peer reviewed publications on axSpA. Professor Sengupta has been an invited speaker for axSpA at several national and international meetings.
The management of Ankylosing Spondylitis and the role of Xeljanz in its treatment.
Introduction to Modular AS Videos
Module 1: The Burden of Disease with Axial Spondyloarthritis and AS
Module 2: Treatment Options in AS
Module 3: An Overview of the Evidence Base Supporting the Use of Xeljanz in AS
Module 4: A Clinicians Perspective in AS
Set up a PfizerPro account to access further materials and resources, and receive communication about medicines and vaccines promoted by Pfizer.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
Find out more about dosing in Ankylosing Spondylitis.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024